Abstract

Rajaganapathy Kaliyaperumal*, Ramalingam Sathiyasundar, Dharman Suresh Lingam and Chidambaram Ganapathy

ABSTRACT

The current work focuses on drug development of known approved antibiotics such as Ceftaroline fosamil was modified its structural core to obtain a novel ceftaroline fosamil analogues library and also a certain novel indole library for the inhibition of SARS-CoV-2, 3CL-Proteases enzyme for against COVID-19, it’s a urgent to generate new chemical entities against this virus. As a key enzyme in the life-cycle of corona-virus, the 3C-like main protease (3CLpro or Mpro) is the most attractive for antiviral drug design. Based on a recently solved structure (PDB ID: 6LU7, SARS/CoV-2 3CL Pro, its 99% identical of COVID-19), Reported as., Yu-Chuan Chang et.al.,2020, we were developed the preliminary work of Structure-based drug design for generating potential lead compounds for targeting against the SARS-CoV-2 3CLpro resulted in the, archived three series of derivatives from those library by our structure-based optimization. These three compounds can be used as potential lead candidates for future drug development of the pharmacological interventions against COVID-19.